Trial Information

Use Of Proteomic Analysis Of Serum Samples For Detection Of Non-Small Cell Lung Cancer

OBJECTIVES:

Primary

- Determine, prospectively, whether serum proteomic profiling can predict the presence of
primary non-small cell lung cancer in patients with clinically suspicious stage I lung
lesions who are undergoing lung resection.

Secondary

- Correlate the serum proteomic profile with pathologic nodal status and histopathologic
features of primary lung cancer in these patients.

- Correlate the initial and follow-up serum proteomic profile with overall and
cancer-specific survival of these patients.

- Correlate changes in the proteomic profile (preoperative to postoperative) with overall
and cancer-specific survival of these patients.

Tertiary

- Determine whether novel molecular strategies can predict the presence of lung cancer
and/or the biologic behavior of an individual cancer in these patients.

OUTLINE: Patients undergo lung resection. Patients also undergo preoperative and
postoperative collection of whole blood and serum for proteomic profiling using
surface-enhanced laser desorption/ionization-time of flight mass spectrometry. A lung tissue
biopsy taken at surgery is also analyzed.

Patients are followed at 60-90 days and then annually for 2-5 years.

PROJECTED ACCRUAL: A total of 1,000 patients will be accrued for this study within 2 years.